| Old Articles: <Older 6211-6220 Newer> |
|---|
 |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.   |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
The Motley Fool
February 24, 2010
Brian Orelli |
Medtronic Needs to Regrow a Spine Everything else looks fairly good, but the problem I see involves the slight decline in Medtronic's second-largest segment, spinal products. |
The Motley Fool
February 23, 2010
Brian Orelli |
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. |
The Motley Fool
February 23, 2010
Brian Orelli |
Triple-Teaming Cancer for Fun and Profit Pfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive. |
The Motley Fool
February 23, 2010
Brian Orelli |
The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
February 22, 2010
Brian Orelli |
A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products. |
The Motley Fool
February 22, 2010
Brian Orelli |
Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
| <Older 6211-6220 Newer> Return to current articles. |
